Insight

Jun 11, 2025, 16:12

Immunotherapy Plus Chemotherapy Before Surgery Improves Long-Term Survival in NSCLC – Johns Hopkins Medicine International

Johns Hopkins Medicine International shared a post on LinkedIn:

“Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study from JohnsHopkins.

‘Just three doses of immunotherapy and chemotherapy showing a survival advantage is a big step forward for patients,’ says Julie Brahmer, M.D., director of thoracic oncology at the Johns Hopkins Kimmel Cancer Center.”

Read “Five-Year Analysis Shows Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery Significantly Improves Long-Term Survival”.

More posts about Johns Hopkins Medicine International on OncoDaily.

cancer cancer deaths chemotherapy immunotherapy Johns Hopkins Kimmel Cancer Center Johns Hopkins Medicine International non small cell lung cancer NSCLC OncoDaily Oncology Thoracic Oncology

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care